Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078286 · ClinicalTrials.gov registry record · Phase 2
Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 469
- Enrollment target
NCT00078286: Completed Phase 2 study, sponsored by Duke University.
NCT00078286 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 469 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (253% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00078286, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 469 participants
- Enrollment target
Study Summary
This study will examine the effect of antidepressant medication on rates of death and disease in depressed people with chronic heart failure.
Primary Outcome
Symptoms of depression (as measured by the Hamilton Depression Rating Scale, HDRS) in congestive heart failure patients with clinical depression after treatment with sertraline or placebo. The 17-item Hamilton Depression Rating Scale (HDRS) is a rater-administered assessment of depression severity, with total score ranges from 0 (not at all depressed) to 52 (most severely depressed). Change in depression was measured as the difference between the 12-week HDRS scores and the baseline HDRS scores
Interventions
- DRUG Placebo
- DRUG Sertraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2003-11 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
What the finished NCT00078286 record still lists
NCT00078286 is an interventional study that assigns participants to a tested intervention. The registered 469 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (253% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00078286 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00078286 about?
NCT00078286 is a clinical study titled "Antidepressant Medication Treatment for Depression in Individuals With Chronic Heart Failure". This study will examine the effect of antidepressant medication on rates of death and disease in depressed people with chronic heart failure.
What is the current status of trial NCT00078286?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 469 participants. The study started on 2003-11. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00078286?
The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG).
Who is sponsoring clinical trial NCT00078286?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00078286's enrollment target sits among peer trials
469 80th of 2000 higher than 1,921 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05256940 · 470 participants · NA
Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide
- NCT05458219 · 470 participants · Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT05850689 · 470 participants · Phase 3
Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- NCT05935384 · 470 participants
SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia